Background: Intravenous use of sufentanil can elicit cough. This study aimed to evaluate the inhibitory effect of pre-injection of a mall dose of remifentanil on sufentanil-induced cough during the induction of general anesthesia. Methods: This prospective, randomized, controlled trial was conducted from January 10, 2019 to March 01, 2019. A total of 100 patients undergoing elective surgery under general anesthesia were enrolled, and at last 84 patients were included and randomly allocated into two equal size groups (n=42): Patients in the Remifentanil group (R group) received an intravenous infusion of remifentanil 0.3 µg/kg (diluted to 2 ml) 1 minute before sufentanil injection; patients in the Control group (C group) received 2 ml of normal saline (NS) at the same time point. Injections of patients in both groups were completed within 5 seconds. Then, sufentanil 0.5 µg/kg was injected within 5 seconds and the number of coughs that occurred within 1 minute after sufentanil injection were recorded. One minute after sufentanil injection, etomidate 0.3 mg/kg and cisatracurium 0.15 mg/kg were given for general anesthesia induction irrespective of the presence or absence of cough. The mean arterial pressure (MAP) and heart rate (HR) at time points just before remifentanil pretreatment administration (T0), 3 minutes after administration (T1), 1 minute after intubation (T2), and 3 minutes after intubation (T3) were recorded. Results:
safely reduced the incidence and severity of cough induced by sufentanil during anesthesia induction and can be used as an alternative treatment to inhibit coughing caused by sufentanil.
Background
Sufentanil has been commonly used for the induction of general anesthesia because of its strong analgesic properties (1) . However, the intravenous use of sufentanil can elicit cough (1, 2) . This side effect may increase intracranial, intraocular, and intraabdominal pressure, which may endanger patients with a cerebral aneurysm, open eye injury or abdominal aortic aneurysm.
Various agents have been used for cough suppression prior to induction of general anesthesia including: 1-intravenous opioid such as fentanyl, 2-intramuscular morphine, 3-dexmedetomidine, 4-magnesium sulfate, 5-terbutaline, 6-lidocaine, and 7-dezocine (1, (3) (4) (5) (6) (7) (8) .
However, because of their more or less potential additional side effects, long onset time, long duration, inconvenience to get, they were somewhat limited in clinical use.
Remifentanil is an opioid that has both short onset time and short duration and is also readily available.
The use of remifentanil for cough suppression has previously been documented (9) (10) (11) (12) (13) . Remifentanil has shown effective cough suppression, however, in few studies, remifentanil has been used prior to the induction of general anesthesia to prevent opioid-induced cough.
Therefore, in this study, we evaluated the effects of remifentanil on the incidence and severity of sufentanil-induced cough during the induction of general anesthesia, thereby aiming to assess whether a small dose of remifentanil could be used as an treatment to inhibit sufentanil-induced cough.
Methods

CONSORT guidelines
This study adheres to CONSORT guidelines.
Participants
This study passed the ethical review by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (2018-150) (Wenzhou, China), and was registered at the Chinese Clinical Trial Registry (ChiCTR1900020587, January 9, 2019). Written informed consent was obtained from all patients.
One hundred patients were screened, and a total of 84 patients were scheduled for elective surgery under general anesthesia (aged 20-70 years), classified as ASA I or II, were selected (shown as Figure 1 ). Exclusion criteria were: smoking; Body Mass Index (BMI) over 28; increased intracranial, intraabdominal or intraocular pressure before operation; a history of respiratory diseases, such as asthma, chronic cough, and upper respiratory tract infection within two weeks; a history of other systemic diseases, including gastroesophageal reflux, hypertension, diabetes, heart disease, impaired kidney or liver function, a history of chronic administration of opioids, cough-causing medications, such as angiotensin-converting-enzyme inhibitors (ACE-inhibitors), and anti-cough medications, such as bronchodilators and steroid therapy.
Anesthesia and research procedure
The trial was conducted from January 10, 2019 to March 01, 2019 at The First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). None of the patients received any premedication. In brief, a 20-gauge cannula was inserted into the dorsum of the hand of each patient and connected to a T-connector for drug administration. Standard ASA monitors were attached, including non-invasive arterial pressure, electrocardiography, and pulse oxygen saturation (SPO 2 ). The 84 patients were randomly and equally divided into two groups: R group for remifentanil 0.3 µg/kg (diluted to 2 ml) intravenous infusion; C group for 2 ml of NS.
All patients were given oxygen via a face mask (6 L/min) before the induction of anesthesia. Injections of both two groups (remifentanil or saline) were completed within 5 seconds. One minute after injection, each patient was given a sufentanil bolus of 0.5 µg/kg within 5 seconds.
The number of coughs that occurred within 1 minute after sufentanil injection were recorded and the severity was graded depending on the cough times (mild, 1-2; moderate, 3-4; and severe, ≥5).
One minute after the injection of sufentanil, etomidate 0.3 mg/kg and cisatracurium 0.15 mg/kg were given for the induction of general anesthesia irrespective of the presence or absence of cough. MAP and HR immediately before remifentanil or NS administration (T0), 3 minutes after administration (T1), 1 minute after intubation (T2), and 3 minutes after intubation (T3) were recorded.
Throughout the experiment, side effects of remifentanil, such as muscle rigidity or other unintended effects were also recorded.
Statistical analysis
Sample size estimates were done using PASS 11 software (PASS, Kaysville, UT, USA).
In our pilot study, the incidence of cough elicited by 0.5 μg/kg of sufentanil was 30% (6/20), which was reduced to 5% (1/20) after pretreatment with remifantanil.
To achieve 80% statistical power with α=0.05, each group would require no less than 32 patients. To account for drop-outs, we recruited 50 patients per group.
Using a computer generated random-number sequence, patients were randomly and equally divided into two groups by. Random allocation sequences were collected, participants were enrolled and assigned to interventions and outcomes were assessed. Both remifentanil (0.3 µg/kg, diluted to 2ml) and NS were injected in a volume of 2 ml. After assignment, both participants and investigators were blinded Normally distributed measurement data, such as age and BMI were presented as the mean ± standard deviation and were analyzed by Student's t test. Non-normally distributed data were presented as the median (Q1, Q3) and were analyzed by Mann-Whitney U test. Numeration data, such as the incidence of cough were presented as absolute or relative effect sizes, and were analyzed by the χ2 test.
Grade data (the severity of coughs) were analyzed by Mann-Whitney U test. The changes in HR and MAP before and after injection between groups were compared using repeated measures analysis of variance.
Statistical analyses were two-tailed and statistical significance was accepted at the 5% probability level.
Results
Demographic characteristics
This trial was conducted from January 10, 2019 to March 01, 2019. A total of 100 eligible patients were screened among which 84 patients participated in our study and were included in the final analyses (four patients declined participation; seven patients had unacceptable hypertension before the start of the study; the anesthetic plans of five patients changed before the study started) ( Figure 1 ).
ASA physical status and demographic characteristics, including gender, age, and the BMI of patients in the two groups were similar (P>0.05, Table 1 ). 
Incidence and severity of cough
The incidence in group C was 31% and in group R was 4.8%. Both the incidence and severity of cough in Group R were significantly lower than those in Group C (p < 0.05, Table 2 ). Both the incidence and severity of cough in patients in Group R were significantly lower compared to those in patients in Group C (P < 0.05).
R= remifentanil; C=control. The severity of cough was graded as mild (1-2), moderate (3-5), or severe (>5) based on the number of cough observed in 60s after sufentanil injection. *Indicates P<0.01 compared with patients in Group C.
Hemodynamic data changes
There was no statistical difference in the data of HR and MAP between two groups at four corresponding time points (p > 0.05, Table 3 and Table 4 ). Values are expressed as mean±standard deviation.
There were no significant differences in ether MAP or HR between the two groups.
R= remifentanil, C=control; T0, time before administration of remifentanil or normal saline; T1: 3 minutes after administration; T2: 1 minute after intubation; T3: 3 minutes after intubation; MAP: mean arterial pressure; HR: heart rate.
Side effects or unintended effects
In both groups, none of the patients showed signs of apnea, muscle rigidity or other unintended effects.
Discussion
In this study, we demonstrated that pretreatment with remifentanil at a small dose of 0.3 μg/kg reduced the incidence and severity of sufentanil-induced cough without influencing the hemodynamics during anesthetic induction. The incidence of cough was 31% in patients in group C and decreased to 4.8% in patients in Group R.
Coughing following the administration of opioid drugs during general anesthesia induction is often reported. In this study, the incidence of cough induced by sufentanil was 31%. In an study by Agarwal et al. Various mechanisms have been proposed to explain opioid-induced cough. A plumonary chemoreflex mediated by either vagal C-fiber receptors close to pulmonary vessels or irritant receptors may play a role in opioid-induced cough (16) . Opioid-induced histamine release (17) and muscle rigidity leading to sudden closure of the vocal cords or supraglottic obstruction by soft tissue(18) may be another possible casual factor for cough. In addition, in several studies, it was demonstrated that opioid receptor dualism might be an important mechanism of opioid-induced cough (3, 8, 19) .
Various pretreatments with drugs, such as lidocaine, terbutaline, dezocine, dexmedetomidine, and magnesium sulfate have been reported to reduce the incidence of opioid-induced cough (1, 5, 6, 8, 20) , however these drugs might add side effects and potential risks. In a study by He et al. (5) , an injection with dexmedetomidine 0.5 μg/kg or 1.0 μg/kg over 10 minutes inhibited cough induced by the subsequent fentanyl (4 μg/kg) intravenous injection. However, this dose of dexmedetomidine has the potential to cause bradycardia and hypotension, therefore an injection that is too slow may cause an issue. In another study (1) In the current study, we found that remifentanil, an opioid that is readily available, with both short onset and duration time, could decrease the incidence and severity However, in the current study, we found that a pre-emptive small dose of 0.3 μg/kg remifentanil reduced cough induced by a subsequent injection with 0.5 μg/kg sufentanil. However, what was used as a pretreatment was another opioid, remifentanil, not sufentanil itself. Hence, the theory of fluctuations in the sufentanil plasma concentration mentioned above seems unlikely.
We hypothesized that opioid receptor dualism may be a possible mechanism to partly explain this phenomenon. One of the common and useful side-effects of opioid analgesics is suppression of the cough reflex, which is the basis of their use in oral cough suppressants (3). Sufentanil, fentanyl, and remifentanil infusion before recovery from general anesthesia have previously been reported to suppress coughing during extubation (9, 21, 22) . Opioids may inhibit the cough reflex by a direct effect on the cough center in the medulla, at doses lower than those required for analgesia (3) . Therefore, we suggested that the anti-tussive effect of preemptive remifentanil in the present study might be related to a centrally-acting effect. The low priming dose of remifentanil might initially exert a central antitussive effect and then inhibit the cough-inducing effect of a subsequent large dose of sufentanil. This hypothesis was partly supported by the study of Phua et al.(3) in which the incidence of fentanyl-induced cough was reduced by intramuscular morphine pretreatment 1 hour before general anesthesia induction . However, this speculation lacks definitive evidence, and therefore additional studies are warranted to verify this hypothesis, and to reveal the underlying mechanism of action.
Given that remifentanil has a respiratory depressive effect, possible apnea-related absence of cough after remifentanil administration must be considered. It is also possible that the dose of remifentanil caused a transient apnea that resulted in an absence of coughing. For example, Remifentanil took 50-60 seconds to reach the effect point, and the apnea took 40-50 seconds, which partially or even completely covered the observation time after sufentanil administration.
Remifentanil may induce muscle rigidity and blood pressure and HR decline (15) . In a study performed by Shen et al (15) , three patients in the rernifenranil group showed muscle rigidity. and one patient had significant bradycardia that required treatment with atropine. However, in our study, none of the patients showed such adverse reactions, which might be due to the very low dose of remifentanil that was used.
Our study has several limitations. Few studies have shown the number doses of remifentanil that are used to suppress cough caused by opioids, therefore, we used a dose of remifentanil that was close to the dose of fentanyl used in the study of pulse oxygen saturation.
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